Search
NewAmsterdam Pharma Company NV
NAMSAdd to Watchlist
27.790USD
-0.670-2.35%
Close 07-31 16:00（ET）Quotes delayed by 15 min
3.25BMarket Cap
LossP/E TTM
More Details of NewAmsterdam Pharma Company NV Company
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
NewAmsterdam Pharma Company NV Info
Ticker SymbolNAMS
Company nameNewAmsterdam Pharma Company NV
IPO dateNov 23, 2022
CEODavidson (Michael Harvey)
Number of employees68
Security typeOrdinary Share
Fiscal year-endNov 23
AddressGooimeer 2-35
CityNAARDEN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryNetherlands
Postal code1411 DC
Phone31352062971
Websitehttps://ir.newamsterdampharma.com/
Ticker SymbolNAMS
IPO dateNov 23, 2022
CEODavidson (Michael Harvey)
Company Executives of NewAmsterdam Pharma Company NV
Name
Name/Position
Position
Shareholding
Change
Mr. John W. Smither
Mr. John W. Smither
Temporary Non-Executive Independent Director
Temporary Non-Executive Independent Director
2.32K
--
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Director
Independent Director
2.32K
--
Dr. James N. Topper, M.D., Ph.D.
Dr. James N. Topper, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Dr. John Kastelein
Dr. John Kastelein
Chief Scientific Officer, Non-Executive Director
Chief Scientific Officer, Non-Executive Director
--
--
Ms. Juliette Audet
Ms. Juliette Audet
Chief Business Officer
Chief Business Officer
--
--
Dr. Louis Lange, M.D., Ph.D.
Dr. Louis Lange, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Nicholas Downing, M.D.
Dr. Nicholas Downing, M.D.
Director
Director
--
--
Ms. Janneke Van Der Kamp
Ms. Janneke Van Der Kamp
Temporary Non-Executive Director
Temporary Non-Executive Director
--
--
Dr. Marc Ditmarsch, M.D.
Dr. Marc Ditmarsch, M.D.
Chief Development Officer
Chief Development Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. John W. Smither
Mr. John W. Smither
Temporary Non-Executive Independent Director
Temporary Non-Executive Independent Director
2.32K
--
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Director
Independent Director
2.32K
--
Dr. James N. Topper, M.D., Ph.D.
Dr. James N. Topper, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Dr. John Kastelein
Dr. John Kastelein
Chief Scientific Officer, Non-Executive Director
Chief Scientific Officer, Non-Executive Director
--
--
Ms. Juliette Audet
Ms. Juliette Audet
Chief Business Officer
Chief Business Officer
--
--
FAQs
Who are the top five shareholders of NewAmsterdam Pharma Company NV?
The top five shareholders of NewAmsterdam Pharma Company NV are: Mr. John W. Smither
How many institutions hold shares of NewAmsterdam Pharma Company NV (NAMS)?
As of 2026Q1, 366 institutions hold shares of NewAmsterdam Pharma Company NV, with a combined market value of approximately 128.70M, accounting for 110.09% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 2432976.00.